. Table 2 specifies that gonadotropin-releasing hormone (GnRH) antagonists should be used as second-line androgen deprivation therapy after GnRH agonists. GnRH antagonists have been evaluated as alternative agents to agonists in the first-line treatment of advanced prostate cancer and although the body of evidence for agonists is greater, the licence for degarelix does not restrict it to second-line use after these agents have failed. Furthermore, the degarelix pivotal phase III trial 2 and its long-term extension 3 demonstrated a number of clinical benefits for degarelix vs. the GnRH agonist, leuprolide. These include a significant improvement in prostate-specific antigen progression-free survival (which is indicative of time to castration-resistance in these patients) 4 and a significant reduction in serum alkaline phosphatase in those with metastatic disease (indicative of control of skeletal metastases).
5
Unlike GnRH agonists, degarelix was not associated with an increased risk of cardiovascular events (based on an analysis of the event rate before and after initiation of degarelix in nine prospective trials; n51704).
6 As Connolly and his colleagues point out in the conclusion of their paper, the increased risk of cardiovascular disease needs to be taken into account when evaluating the riskbenefit ratio of androgen deprivation therapy. . Like GnRH agonists, degarelix is licensed to treat advanced prostate cancer rather than the metastatic prostate cancer as specified in Tables 1 and 2 Many thanks for bringing these points to the attention of the authors.
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